Hoyer D, Lery H, Waeber C, Bruinvels A T, Nozulak J, Palacios J M
Preclinical Research, Sandoz Pharma Ltd, Basel, Switzerland.
Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):249-54. doi: 10.1007/BF00173536.
Radioligand binding studies were performed in membranes of rabbit whole brain and striatum using the novel iodinated radioligand for 5-hydroxytryptamine 5-HT1B and 5-HT1D sites, Serotonin-5-O-Carboxymethyl-Glycyl[125I]Tyrosinamide ([125I]GTI). [125I]GTI labelled a finite number of high affinity sites in rabbit brain membranes, Bmax = 191 +/- 47 fmol/mg protein, pKD (-log mol/l) = 8.50 +/- 0.13, n = 5. The pharmacological profile of [125I]GTI binding was fully comparable to that reported previously in human and other brain preparations known to possess 5-HT1D sites (using either [3H]5-HT or [125I]GTI) and displayed a characteristic rank order of affinity: 5-carboxamido-tryptamine greater than 5-HT = dihydroergotamine greater than or equal to ergotamine greater than or equal to sumatriptan greater than or equal to CGS 12066 greater than or equal to metergoline greater than yohimbine greater than or equal to methysergide greater than ICYP greater than 8-OH-DPAT greater than or equal to CP 93129 greater than (-)pindolol greater than ketanserin greater than isamoltane greater than mesulergine greater than corynanthine greater than buspirone greater than MDL 72222. Autoradiographic studies were performed on rabbit brain slices using [3H]5-HT in the presence of 100 nmol/l 8-OH-DPAT and mesulergine (in order to mask 5-HT1A and 5-HT1C binding sites) and [125I]CYP (iodocyanopindolol) in the presence of 3 mumol/l isoprenaline and 100 nmol/l 8-OH-DPAT (in order to mask beta adrenoceptor and 5-HT1A binding sites). There was no detectable specific binding of [125I]CYP through the brain, thus excluding the presence of 5-HT1B sites in rabbit brain.(ABSTRACT TRUNCATED AT 250 WORDS)
使用新型碘化放射性配体5-羟色胺5-HT1B和5-HT1D位点的血清素-5-O-羧甲基-甘氨酰[125I]酪氨酸酰胺([125I]GTI),在兔全脑和纹状体膜中进行放射性配体结合研究。[125I]GTI在兔脑膜中标记了有限数量的高亲和力位点,Bmax = 191 +/- 47 fmol/mg蛋白质,pKD(-log mol/l) = 8.50 +/- 0.13,n = 5。[125I]GTI结合的药理学特征与先前在已知具有5-HT1D位点的人和其他脑制剂中报道的特征完全可比(使用[3H]5-HT或[125I]GTI),并显示出特征性的亲和力顺序:5-羧酰胺色胺大于5-HT = 二氢麦角胺大于或等于麦角胺大于或等于舒马曲坦大于或等于CGS 12066大于或等于美替拉酮大于育亨宾大于或等于甲基麦角新碱大于ICYP大于8-OH-DPAT大于或等于CP 93129大于(-)吲哚洛尔大于酮色林大于异戊烷大于甲磺酰麦角新碱大于育亨宾大于丁螺环酮大于MDL 72222。在100 nmol/l 8-OH-DPAT和甲磺酰麦角新碱存在下(为了掩盖5-HT1A和5-HT1C结合位点),使用[3H]5-HT对兔脑切片进行放射自显影研究;在3 μmol/l异丙肾上腺素和100 nmol/l 8-OH-DPAT存在下(为了掩盖β肾上腺素能受体和5-HT1A结合位点),使用[125I]CYP(碘氰吲哚洛尔)进行放射自显影研究。在整个脑中未检测到[125I]CYP的特异性结合,因此排除了兔脑中存在5-HT1B位点。(摘要截断于250字)